| Literature DB >> 19210692 |
M Haidinger1, M Hecking, M Memarsadeghi, T Weichhart, J Werzowa, W H Hörl, M D Säemann.
Abstract
Interference with T-cell function increases the risk of infections, especially during the early post-transplant period. Belatacept, a costimulation blocker, is currently being tested in phase III clinical trials. Here we report a renal transplant recipient who received belatacept and developed severe Pneumocystis jirovecii pneumonia (PCP) with fatal superinfections 4 years post transplant. Cytomegalovirus infection preceded PCP, which typically occurs in overimmunosuppressed patients, but has not yet been reported under T-cell costimulation blockade in transplant patients. This case illustrates the possibility of excessive immunosuppression even with a lymphocyte-specific regimen.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19210692 DOI: 10.1111/j.1399-3062.2009.00366.x
Source DB: PubMed Journal: Transpl Infect Dis ISSN: 1398-2273 Impact factor: 2.228